Only 1 case in each arm was newly diagnosed, and all patients harbored an IDH1 mutation, though this was not required for eligibility, and 1 patient received neoadjuvant vaccine prior to glioma diagnosis. The gene discussed is IDH1; the disease is central nervous system cancer.